Skip to main content
    T

    Theravance Biopharma Inc (TBPH)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $17.03
    +0.00 (+0.00%)

    Market Cap: $884.18M

    Last updated: Oct 14, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    44%(17/39)
    Avg Surprise
    -12.97%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.20
    Range$0.20 - $0.20
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.200.0%
    60d ago$0.200.0%
    30d ago$0.200.0%
    7d ago$0.200.0%
    Current$0.20
    Revenue Consensus
    $21M
    Range$20M - $21M
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.15
    Range$-0.15 - $-0.15
    1 analysts
    Revenue Consensus
    $30M
    Range$17M - $57M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.15---
    Sep 26EST
    		-$0.20---
    Jun 26
    Reported Aug 10
    		$0.07$0.14-50.00%Miss-93.5%
    Mar 26
    Reported May 7
    		$0.01N/A-88.89%Miss+105.9%
    Dec 25
    Reported Mar 19
    		$0.06N/A-94.10%Miss+217.8%
    Sep 25
    Reported Nov 10
    		$0.04$-0.05+180.00%Beat+166.7%
    Jun 25
    Reported Aug 12
    		$1.08$0.67+61.19%Beat+930.8%
    Mar 25
    Reported May 8
    		$-0.17$-0.09-88.89%Miss-88.9%
    Dec 24
    Reported Feb 26
    		$-0.05$-0.08+39.86%Beat-267.0%
    Sep 24
    Reported Nov 12
    		$-0.06$-0.10+40.00%Beat-500.0%
    Jun 24
    Reported Aug 5
    		$-0.13$-0.07-85.71%Miss+0.0%
    Mar 24
    Reported May 13
    		$-0.09$-0.12+25.00%Beat+62.5%
    Dec 23
    Reported Feb 26
    		$0.03N/A+120.00%Beat+120.0%
    Sep 23
    Reported Nov 7
    		$-0.01N/A+88.89%Beat+90.0%
    Jun 23
    Reported Aug 7
    		$-0.13$-0.11-18.18%Miss-244.4%
    Mar 23
    Reported May 8
    		$-0.24$-0.20-20.00%Miss-9.1%
    Dec 22
    Reported Feb 27
    		$-0.15$-0.17+11.76%Beat+65.1%
    Sep 22
    Reported Nov 7
    		$-0.10$-0.04-150.00%Miss+78.3%
    Jun 22
    Reported Aug 4
    		$0.09$0.15-40.00%Miss+111.3%
    Mar 22
    Reported May 5
    		$-0.22$0.10-320.00%Miss+82.3%
    Dec 21
    Reported Feb 23
    		$-0.43$-0.33-30.30%Miss+53.3%
    Sep 21
    Reported Nov 3
    		$-0.46$-0.52+11.54%Beat+60.3%
    Jun 21
    Reported Aug 3
    		$-0.80$-0.88+9.09%Beat+20.0%
    Mar 21
    Reported May 4
    		$-1.24$-0.79-56.96%Miss-8.8%
    Dec 20
    Reported Feb 23
    		$-0.92$-1.02+9.80%Beat+21.4%
    Sep 20
    Reported Nov 5
    		$-1.16$-0.88-31.82%Miss-10.5%
    Jun 20
    Reported Aug 6
    		$-1.00$-0.88-13.64%Miss-38.9%
    Mar 20
    Reported May 6
    		$-1.14$-1.00-14.00%Miss+13.6%
    Dec 19
    Reported Feb 24
    		$-1.17$-1.13-3.54%Miss-27.2%
    Sep 19
    Reported Nov 5
    		$-1.05$-1.11+5.41%Beat+4.5%
    Jun 19
    Reported Jul 31
    		$-0.72$-1.24+41.94%Beat+5.3%
    Mar 19
    Reported May 7
    		$-1.32$-1.19-10.92%Miss-8.2%
    Dec 18
    Reported Feb 26
    		$-0.92$-1.06+13.21%Beat+43.9%
    Sep 18
    Reported Nov 6
    		$-1.10$-1.14+3.51%Beat+13.4%
    Jun 18
    Reported Aug 1
    		$-0.76$-1.23+38.21%Beat+40.2%
    Mar 18
    Reported May 8
    		$-1.22$-1.36+10.29%Beat+3.9%
    Dec 17
    Reported Feb 27
    		$-1.64$-1.16-41.38%Miss-20.6%
    Sep 17
    Reported Nov 7
    		$-1.27$-1.14-11.40%Miss-
    Jun 17
    Reported Aug 8
    		$-1.27$-1.17-8.55%Miss-
    Mar 17
    Reported May 9
    		$-1.27$-1.18-7.63%Miss-
    Dec 16
    Reported Feb 27
    		$-1.36$-1.05-29.52%Miss-

    Key Metrics

    Valuation
    P/E Ratio95.14EV/EBITDA53.91x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin51.60%Operating Margin8.89%
    ROE20.90%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage33.20x
    Current Ratio13.54xQuick Ratio13.54x
    Trading Statistics
    Beta0.24Avg Volume2.68M
    52-Week High$21.0352-Week Low$13.08

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$17.03
    SMA 20$17.03
    SMA 50$17.01
    SMA 200$17.09
    EMA 10$17.03
    EMA 20$17.03
    EMA 50$16.99
    EMA 200$16.49

    MACD

    Line: 0.00Signal: 0.01Hist: -0.00

    ADX

    ADX: 44.3+DI: 25.3-DI: 9.5

    Aroon & PSAR

    Aroon Up36.0
    Aroon Down8.0
    PSAR$17.16

    Bollinger Bands

    Upper Band$17.04
    Lower Band$17.02
    %B Position13%(Lower)
    Band Width0.45

    RSI (14-Day)

    Neutral
    53.2

    Momentum Oscillators

    Stoch %K6.7
    Stoch %D12.2
    Williams %RN/A
    ROC (10d)N/A
    MomentumN/A
    CCI (20d)-41.7
    MFI (14d)N/A

    Volatility Measures

    ATR (14d)$0.02(0.1%)
    StdDev (20d)0.01
    Hist Vol0.9%(Low)

    Volume Flow

    VWAP$17.03
    OBV8.2M
    AD Line-9.8M
    CMF (20d)-0.704

    Volume Metrics

    Avg Vol (20d)894.4K
    Vol RatioN/A
    VWMA (20d)$17.03

    Pivot Points

    R3$17.03
    R2$17.03
    R1$17.03
    Pivot Point$17.03
    S1$17.03
    S2$17.03
    S3$17.03

    Advanced Oscillators

    TSI7.11
    Ultimate OscN/A
    KST0.60

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$20.73M$17.70M$45.89M$19.99M$26.20M$15.39M$18.75M$16.87M$14.26M$14.50M$17.57M$15.69M
    Cost of Revenue$0$0$1.51M$0$0$0$9.45M$0$0$0$8.31M$0
    Gross Profit$20.73M$17.70M$45.89M$19.99M$26.20M$15.39M$18.75M$16.87M$14.26M$14.50M$17.57M$15.69M
    Operating Expenses$29.01M$27.18M$25.88M$26.45M$28.92M$29.82M$27.95M$27.70M$29.96M$25.71M$23.80M$24.45M
    R&D$4.71M$5.83M$7.36M$8.11M$10.49M$11.45M$9.45M$9.27M$9.95M$8.97M$8.31M$8.31M
    SG&A$14.18M$17.72M$18.52M$18.33M$18.43M$18.37M$18.50M$16.88M$17.06M$16.74M$15.49M$16.14M
    Operating Income$-8,277,000$-9,483,000$20.01M$-6,455,000$-2,725,000$-14,434,000$-9,200,000$-10,837,000$-15,705,000$-11,207,000$-6,240,000$-8,760,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$582,000$573,000$663,000$643,000$643,000$630,000$644,000$629,000$623,000$609,000
    Income Before Tax$-4,791,000$-6,470,000$73.07M$-2,889,000$73.21M$-14,138,000$-8,939,000$-10,052,000$-15,221,000$-10,402,000$-5,016,000$-7,583,000
    Income Tax Expense$1.11M$-1,537,000$12.04M$-6,504,000$18.37M$-559,000$6.59M$2.65M$1.31M$1.26M$3.49M$1.37M
    Net Income$-5,898,000$-4,933,000$61.02M$3.62M$54.84M$-13,579,000$-15,527,000$-12,698,000$-16,529,000$-11,664,000$-8,510,000$-8,950,000
    EBITDA$-4,285,000$-5,635,000$23.85M$-1,680,000$74.80M$-12,443,000$-7,601,000$-8,660,000$-13,598,000$-8,594,000$-2,976,000$-6,037,000
    EBIT$-4,791,000$-6,470,000$23.65M$-2,316,000$73.87M$-13,495,000$-8,296,000$-9,422,000$-14,577,000$-9,773,000$-4,393,000$-6,974,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TBPH

    News

    [Form 4] Theravance Biopharma, Inc. Insider Trading Activity

    This Form 4 filing details insider trading activity for Theravance Biopharma, Inc. (TBPH) related to a merger where the company became a wholly-owned subsidiary of Zymeworks Inc. Insider Weiss Asset Management LP...

    Stock Titan•9/28/26•Neutral

    Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal

    Zymeworks (NASDAQ: ZYME) finalized its acquisition of Theravance Biopharma, updating its 2026 financial guidance. The biotechnology company projects revenue between $278 million and $292 million and adjusted EBITDA...

    Benzinga•9/28/26•Neutral

    Theravance Biopharma: Acquisition brings YUPELRI and R&D assets, diversifying revenue and enabling future growth

    Theravance Biopharma (0TB) has announced an acquisition that incorporates YUPELRI and a robust R&D portfolio, aiming to diversify revenue and strengthen its financial standing. The deal...

    TradingView•9/28/26•Bullish

    Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition

    Zymeworks Inc. has announced updated 2026 financial guidance and the final transaction details after completing its acquisition of Theravance Biopharma. The acquisition adds YUPELRI® to Zymeworks' portfolio...

    GlobeNewswire•9/28/26•Neutral

    Theravance Biopharma (TBPH) shares were canceled on September 23 after its Zymeworks merger.

    This article reports on a SCHEDULE 13D/A SEC filing by four entities (Weiss Asset Management, BIP GP LLC, WAM GP LLC, and Andrew M. Weiss) for Theravance Biopharma (TBPH)...

    Stock Titan•9/25/26•Neutral

    TBPH Valuation and Fair Value

    P/E
    95.1x
    Forward P/E
    9.7x
    EV/EBITDA
    53.9x
    PEG
    -0.1x
    P/B
    3.0x
    See GNG's fair value

    TBPH Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    8.9%
    Net margin
    51.6%
    ROE
    20.9%
    FCF margin
    51.5%

    TBPH Competitors

    CompanyTicker
    Beta Bionics, Inc. Common StockBBNX
    MoonLake ImmunotherapeuticsMLTX
    Quidel CorporationQDEL
    Rigel Pharmaceuticals IncRIGL
    MannKind CorpMNKD
    Kura Oncology IncKURA
    Savara IncSVRA
    Si-Bone IncSIBN

    Sector: Healthcare

    TBPH Analyst Ratings

    Consensus
    Hold
    Analysts
    5
    Strong Buy
    0
    Buy
    0
    Hold
    5
    Sell
    0
    Strong Sell
    0

    TBPH Bull Case vs Bear Case

    Bull case

    • TBPH converts 51.5% of revenue into free cash flow.
    • TBPH has a 51.6% net profit margin.

    Bear case

    • TBPH trades at 95.1x trailing earnings.
    • TBPH's quarterly revenue changed -20.9% year over year.

    TBPH Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -0.1%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.20
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About TBPH

    Does TBPH pay dividends?

    Theravance Biopharma Inc (TBPH) does not currently pay a regular dividend.

    What is TBPH's P/E ratio?

    Theravance Biopharma Inc has a price-to-earnings (P/E) ratio of 95.14.

    What is TBPH's market cap?

    Theravance Biopharma Inc (TBPH) has a market capitalization of $884.18M with a current stock price of $17.03.

    Related stocks

    Sector: Healthcare

    All stocks starting with T

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In